These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 16262525)

  • 1. Antisense oligonucleotides and the rational design of new antitumor drugs.
    Prieto J; Hernández-Alcoceba R
    Rev Esp Enferm Dig; 2005 Jul; 97(7):467-71. PubMed ID: 16262525
    [No Abstract]   [Full Text] [Related]  

  • 2. Suppression of pancreatic and colon cancer cells by antisense K-ras RNA expression vectors.
    Aoki K; Ohnami S; Yoshida T
    Methods Mol Med; 2005; 106():193-204. PubMed ID: 15375317
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical development of antisense oligonucleotides as anti-cancer therapeutics.
    Chen HX
    Methods Mol Med; 2003; 75():621-36. PubMed ID: 12407768
    [No Abstract]   [Full Text] [Related]  

  • 4. Antisense oligonucleotides.
    Herdewijn P
    Verh K Acad Geneeskd Belg; 1996; 58(4):359-81. PubMed ID: 8956554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antisense anticancer oligonucleotide therapeutics.
    Wang H; Prasad G; Buolamwini JK; Zhang R
    Curr Cancer Drug Targets; 2001 Nov; 1(3):177-96. PubMed ID: 12188878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antisense treatment directed against mutated Ki-ras in human colorectal adenocarcinoma.
    Andreyev HJ; Ross PJ; Cunningham D; Clarke PA
    Gut; 2001 Feb; 48(2):230-7. PubMed ID: 11156646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical studies of antisense oligonucleotides for cancer therapy.
    Orr RM; Dorr FA
    Methods Mol Med; 2005; 106():85-111. PubMed ID: 15375314
    [No Abstract]   [Full Text] [Related]  

  • 8. Utility of antioncogene ribozymes and antisense oligonucleotides in reversing drug resistance.
    Funato T
    Methods Mol Med; 2005; 106():215-33. PubMed ID: 15375319
    [No Abstract]   [Full Text] [Related]  

  • 9. Combined effect of 2-5A-linked antisense against telomerase RNA and conventional therapies on human malignant glioma cells in vitro and in vivo.
    Iwado E; Daido S; Kondo Y; Kondo S
    Int J Oncol; 2007 Nov; 31(5):1087-95. PubMed ID: 17912434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cooperative antitumor effect of mixed backbone oligonucleotides targeting protein kinase A in combination with cytotoxic drugs or biologic agents.
    Tortora G; Caputo R; Damiano V; Bianco R; Pepe S; Pomatico G; Bianco AR; Jiang Z; Agrawal S; Ciardiello F
    Antisense Nucleic Acid Drug Dev; 1998 Apr; 8(2):141-5. PubMed ID: 9593054
    [No Abstract]   [Full Text] [Related]  

  • 11. Re: Blocking oncogenic Ras signaling for cancer therapy.
    Canevari S; Biocca S; Figini M
    J Natl Cancer Inst; 2002 Jul; 94(13):1031-2; author reply 1032. PubMed ID: 12096090
    [No Abstract]   [Full Text] [Related]  

  • 12. Molecular approaches to cancer therapy.
    Israel MA
    Adv Cancer Res; 1993; 61():57-85. PubMed ID: 8346720
    [No Abstract]   [Full Text] [Related]  

  • 13. [Antisense nucleic acids and gene therapy].
    Saison-Behmoaras E
    Bull Cancer; 1995 Mar; 82(3):224-5. PubMed ID: 7655155
    [No Abstract]   [Full Text] [Related]  

  • 14. Antisense oligonucleotides as therapeutic agents.
    Alama A; Barbieri F; Cagnoli M; Schettini G
    Pharmacol Res; 1997 Sep; 36(3):171-8. PubMed ID: 9367660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antisense oligonucleotides with antitumor activity].
    Otvös L; Sági G
    Magy Onkol; 2004; 48(3):221-7. PubMed ID: 15520872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antisense therapy specific to mutated K-ras gene in hamster pancreatic cancer model. Can it inhibit the growth of 5-FU and MMC-resistant metastatic and remetastatic cell lines?
    Morioka CY; Saito S; Machado MC; Ohzawa K; Kubrusly MS; Cunha JE; Watanabe A
    In Vivo; 2004; 18(2):113-7. PubMed ID: 15113037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antisense oligonucleotides: a new therapeutic approach.
    Temsamani J; Guinot P
    Biotechnol Appl Biochem; 1997 Oct; 26(2):65-71. PubMed ID: 9357101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting telomerase by antisense-based approaches: perspectives for new anti-cancer therapies.
    Folini M; Zaffaroni N
    Curr Pharm Des; 2005; 11(9):1105-17. PubMed ID: 15853659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antisense therapeutics in oncology: points to consider in their clinical evaluation.
    Mani S; Gu Y; Wadler S; Fingert H
    Antisense Nucleic Acid Drug Dev; 1999 Dec; 9(6):543-7. PubMed ID: 10645781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antisense gene therapy using anti-k-ras and antitelomerase oligonucleotides in colorectal cancer.
    Lledó S; Alfonso R; Aliño SF
    Rev Esp Enferm Dig; 2005 Jul; 97(7):472-80. PubMed ID: 16262526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.